Mometasone Eg (Mometasone Furoate Anhydrous)

Mometasone furoate binds to glucocorticoid receptors inside nasal mucosal cells. This interaction modifies gene expression, lowering the production of inflammatory cytokines and mediators. The result is decreased swelling, mucus formation, and immune cell infiltration, which eases the symptoms of allergic rhinitis.

The specific dosing regimen for Mometasone Eg is determined by the prescribing healthcare professional. Typically, the product is administered as one or two sprays per nostril once daily, but the exact number of sprays, frequency, and duration should follow the prescriber’s instructions.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using the product.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mometasone furoate and fluticasone propionate are both intranasal corticosteroids with similar anti‑inflammatory potency. Mometasone often requires a lower daily spray volume due to its high receptor affinity, while fluticasone may have a slightly longer half‑life. Clinical choice depends on patient response, tolerability, and prescriber preference.

Store the nasal spray at room temperature, ideally below 25 °C, in its original packaging. Keep the container tightly closed, protect it from moisture and direct sunlight, and avoid freezing. Do not use the product after the expiration date printed on the label.

Before use, gently shake the bottle and prime it by spraying a few times into the air until a fine mist appears. Tilt the head slightly forward, insert the nozzle into one nostril, close the opposite nostril with a finger, and spray the prescribed number of sprays. Repeat in the other nostril if directed.

Serious adverse events, although rare, include nasal septal perforation, adrenal suppression with prolonged high‑dose therapy, cataracts or glaucoma, severe allergic reactions such as anaphylaxis, and opportunistic fungal infections of the nasal cavity. Patients should seek medical attention promptly if any of these occur.

Mometasone Eg should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It is also contraindicated in patients with active untreated nasal infections, recent nasal surgery, or severe ocular conditions such as uncontrolled glaucoma without medical supervision.